mProX™ Human SIGLEC10 Stable Cell Line

Li, Song. et al. "IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy." Antibody therapeutics, 2023.
This study examines the anti-tumor effects of IMM47, a humanized monoclonal antibody targeting CD24. Techniques such as biolayer interferometry, ELISA, and flow cytometry were utilized to assess IMM47's binding, affinity, and activities in mediating antibody-dependent cellular cytotoxicity, phagocytosis, and complement-dependent cytotoxicity. The results demonstrate the potential of IMM47 as a therapeutic option for CD24-expressing tumors.
Li, Song. et al. "IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy." Antibody therapeutics, 2023.
Pubmed: 37846296   DOI: 10.1093/abt/tbad020

Li, Baozhu. et al. "Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC." International immunopharmacology, 2023.
Recent studies have shown that oxaliplatin, a chemotherapy drug commonly used to treat advanced cancer patients, has limited clinical application due to its tolerability. In various solid tumors, such as hepatocellular carcinoma (HCC), the presence of tumor-associated macrophages has been linked to a poorer prognosis and resistance to oxaliplatin. Thus, targeting these macrophages may improve the effectiveness of oxaliplatin in HCC treatment. A potential target, CD24, has been identified as a novel tumor therapy that inhibits macrophage phagocytosis by interacting with the inhibitory receptor Siglec-10. In this study, the researchers used RNAi technology to inhibit CD24 expression in tumor cells and combined it with oxaliplatin. This resulted in decreased tumor invasion, migration, and proliferation, as well as increased cell apoptosis. Additionally, both the single treatment and combination treatment groups showed enhanced infiltration of immune cells, as observed through immunofluorescence and flow cytometry. This study presents a promising approach for identifying combination therapy and targets to improve the clinical treatment of HCC with oxaliplatin.
Li, Baozhu. et al. "Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC." International immunopharmacology, 2023.
Pubmed: 37827056   DOI: 10.1016/j.intimp.2023.111025